Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS

A sensitive and selective ultra‐high performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) method for the simultaneous determination of seven oral oncolytics (two PARP inhibitors, i.e. olaparib and niraparib, and five tyrosine kinase inhibitors, i.e. cobimetinib, cabozantinib, dabr...

Descripción completa

Detalles Bibliográficos
Autores principales: Krens, Stefanie D., van der Meulen, Eric, Jansman, Frank G.A., Burger, David M., van Erp, Nielka P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065026/
https://www.ncbi.nlm.nih.gov/pubmed/31758580
http://dx.doi.org/10.1002/bmc.4758

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065026/
https://www.ncbi.nlm.nih.gov/pubmed/31758580
http://dx.doi.org/10.1002/bmc.4758

Ejemplares similares